Realcan Pharmaceutical Group , Ltd. EBIT

Realcan Pharmaceutical Group , Ltd. (002589.SZ) currently reports a EBIT of $81M as of September 2026. That compares with $180M in the prior-year period — down 55.6% year over year. That is below the sector sector average of $2.6T. Use the charts on this page to explore Realcan Pharmaceutical Group , Ltd.'s EBIT history and peer comparisons.

Realcan Pharmaceutical Group , Ltd.'s EBIT decreased from $180M to $81M — a 55.6% year-over-year decrease (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Realcan Pharmaceutical Group , Ltd.'s EBIT of $81M is lower than the its sector sector average of $2.6T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Realcan Pharmaceutical Group , Ltd. reported $81M in EBIT as of September 2026. That compares with $180M in the prior-year period — down 55.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $81M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $2.6T. From there, open related valuation or income-statement pages for Realcan Pharmaceutical Group , Ltd., and consider following 002589.SZ for alerts when major investors trade the stock.